[ad_1]
"Food and medicine": medicine "Larotrectinib" to "Vitrakvi" serves a specific segment of cancer patients
The FDA has explained that the drug Larotrectinib (Vitrakvi) serves a specific segment of cancer patients, but not all.
In a statement released today, the FDA announced that some local and international media had recently approved the registration of Larotrectinib, a drug known as Vitrakvi, intended to treat certain types of cancer. This news and news talk about the benefits of drugs, to the point of suggesting the ability of this drug to treat all tumors.
"Lartigectinib (Vitrakvi) is an innovative way to prevent the growth of tumors caused by a rare genetic defect (genetic mutation), which causes certain cancers, which allows the drug to serve and treat a specific group of patients, not all cancer patients.
The drug has received accelerated accreditation from the FDA, a measure adopted by the WHO for drugs that work in innovative ways or that could form the nucleus of a promising therapeutic future.
The study included 55 patients, including 12 patients under 18 years of age with rare genetic mutation (NTRK). The response to the drug in months The first nine were good, reaching 73% of patients, but gradually decreasing to 39% of patients after the first year, highlighting the most significant adverse effects observed in patients who took this drug and the more common: tiredness, nausea, vomiting, diarrhea and constipation
The SFDA said that options and treatment methods for cancer patients were growing. They will be available once they have been subjected to studies on safety and security, confirming that they are following scientific developments related to drugs or therapeutic methods and seeking to provide the patient with drugs and medicines. safe and effective treatment methods.
Source link
